ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 36 filers reported holding ASCENDIS PHARMA A/S in Q1 2015. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2019 | $16,972,000 | -46.4% | 144,194 | -71.5% | 0.65% | -48.6% |
| Q4 2018 | $31,644,000 | +39.6% | 505,098 | +57.8% | 1.27% | +56.0% |
| Q3 2018 | $22,675,000 | -29.3% | 320,000 | -33.7% | 0.81% | -28.0% |
| Q2 2018 | $32,094,000 | +1.7% | 482,467 | 0.0% | 1.13% | +3.1% |
| Q1 2018 | $31,553,000 | -0.2% | 482,467 | -38.9% | 1.09% | -12.1% |
| Q4 2017 | $31,607,000 | +2.6% | 789,000 | -7.2% | 1.24% | -10.4% |
| Q3 2017 | $30,813,000 | +164.6% | 850,000 | +102.6% | 1.39% | +123.5% |
| Q2 2017 | $11,644,000 | -55.2% | 419,453 | -54.9% | 0.62% | -38.1% |
| Q1 2017 | $26,018,000 | +22.4% | 929,226 | -11.5% | 1.00% | +14.8% |
| Q4 2016 | $21,252,000 | +5659.3% | 1,050,000 | +4933.8% | 0.87% | +7183.3% |
| Q2 2015 | $369,000 | -89.4% | 20,859 | -89.6% | 0.01% | -89.3% |
| Q1 2015 | $3,470,000 | – | 200,000 | – | 0.11% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 1,797,745 | $265,886,000 | 19.06% |
| RA Capital Management | 4,914,955 | $726,922,000 | 14.16% |
| Sofinnova Investments, Inc. | 1,109,874 | $164,150,000 | 10.35% |
| Eventide Asset Management | 1,709,848 | $252,887,000 | 5.50% |
| Asymmetry Capital Management, L.P. | 47,599 | $7,040,000 | 5.39% |
| BERYLSON CAPITAL PARTNERS, LLC | 58,200 | $8,608,000 | 5.30% |
| Avoro Capital Advisors LLC | 1,750,000 | $258,825,000 | 5.12% |
| Eversept Partners, LP | 220,344 | $32,588,878 | 4.47% |
| Spyglass Capital Management LLC | 452,104 | $66,866,000 | 4.14% |
| Orbimed Advisors | 1,562,986 | $231,166,000 | 3.25% |